Kontafarma China Holdings (HKSE:01312) Days Sales Outstanding : 51.57 (As of Dec. 2023)

View and export this data going back to 2012. Start your Free Trial

What is Kontafarma China Holdings Days Sales Outstanding?

Kontafarma China Holdings's average Accounts Receivable for the six months ended in Dec. 2023 was HK$106.9 Mil. Kontafarma China Holdings's Revenue for the six months ended in Dec. 2023 was HK$378.4 Mil. Hence, Kontafarma China Holdings's Days Sales Outstanding for the six months ended in Dec. 2023 was 51.57.

The historical rank and industry rank for Kontafarma China Holdings's Days Sales Outstanding or its related term are showing as below:

HKSE:01312' s Days Sales Outstanding Range Over the Past 10 Years
Min: 50.75 Med: 100.64 Max: 205.71
Current: 50.75

During the past 13 years, Kontafarma China Holdings's highest Days Sales Outstanding was 205.71. The lowest was 50.75. And the median was 100.64.

HKSE:01312's Days Sales Outstanding is ranked better than
71.24% of 998 companies
in the Drug Manufacturers industry
Industry Median: 71.845 vs HKSE:01312: 50.75

Kontafarma China Holdings's Days Sales Outstanding increased from Dec. 2022 (49.89) to Dec. 2023 (51.57).

Kontafarma China Holdings Days Sales Outstanding Historical Data

The historical data trend for Kontafarma China Holdings's Days Sales Outstanding can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Kontafarma China Holdings Days Sales Outstanding Chart

Kontafarma China Holdings Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Days Sales Outstanding

Get a 7-Day Free Trial

205.71

95.64

72.04

53.81

51.91

Kontafarma China Holdings Semi-Annual Data
	Jun14	Dec14	Jun15	Dec15	Jun16	Dec16	Jun17	Dec17	Jun18	Dec18	Jun19	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23	Dec23
Days Sales Outstanding	Get a 7-Day Free Trial															64.47	52.29	49.89	48.93	51.57

Competitive Comparison of Kontafarma China Holdings's Days Sales Outstanding

For the Drug Manufacturers - Specialty & Generic subindustry, Kontafarma China Holdings's Days Sales Outstanding, along with its competitors' market caps and Days Sales Outstanding data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Kontafarma China Holdings's Days Sales Outstanding Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Kontafarma China Holdings's Days Sales Outstanding distribution charts can be found below:

* The bar in red indicates where Kontafarma China Holdings's Days Sales Outstanding falls into.

Kontafarma China Holdings Days Sales Outstanding Calculation

Days Sales Outstanding measures the average number of days that a company takes to collect revenue after a sale has been made. It is a financial ratio that illustrates how well a company's Accounts Receivable are being managed.

Accounts Receivable can be measured by Days Sales Outstanding.

Kontafarma China Holdings's Days Sales Outstanding for the fiscal year that ended in Dec. 2023 is calculated as

	Days Sales Outstanding (A: Dec. 2023 )
=	Average Accounts Receivable					/	Revenue	*	Days in Period
=	( (Accounts Receivable (A: Dec. 2022 )	+	Accounts Receivable (A: Dec. 2023 ))	/	count )	/	Revenue (A: Dec. 2023 )	*	Days in Period
=	( (123.644	+	106.518)	/	2 )	/	809.107	*	365
=	115.081					/	809.107	*	365
=	51.91

Kontafarma China Holdings's Days Sales Outstanding for the quarter that ended in Dec. 2023 is calculated as:

	Days Sales Outstanding (Q: Dec. 2023 )
=	Average Accounts Receivable					/	Revenue	*	Days in Period
=	( (Accounts Receivable (A: Jun. 2023 )	+	Accounts Receivable (A: Dec. 2023 ))	/	count )	/	Revenue (A: Dec. 2023 )	*	Days in Period
=	( (107.325	+	106.518)	/	2 )	/	378.402	*	365 / 2
=	106.9215					/	378.402	*	365 / 2
=	51.57

Kontafarma China Holdings (HKSE:01312) Days Sales Outstanding Explanation

For retailers, when we compare Days Sales Outstanding, it is important to compare the same period in the previous years.

Kontafarma China Holdings Days Sales Outstanding Related Terms

Thank you for viewing the detailed overview of Kontafarma China Holdings's Days Sales Outstanding provided by GuruFocus.com. Please click on the following links to see related term pages.

Kontafarma China Holdings (HKSE:01312) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Kontafarma China Holdings Ltd (HKSE:01312) » Definitions » Days Sales Outstanding

Traded in Other Exchanges

N/A

Address

30 Harbour Road, Room 12A 09-20, 12th Floor, Sun Hung Kai Centre, Wanchai, Hong Kong, HKG

Website

https://www.kontafarma.com.hk

Kontafarma China Holdings Ltd is principally engaged in the manufacture and sale of prescription drugs including chemical drugs and traditional Chinese medicine in the PRC, and the operation of fitness centers, provision of fitness and health consulting services, and the operation of franchises. The operating segments include pharmaceutical business and Fitness business. Majority of its revenue derives from pharmaceutical business segment.

Kontafarma China Holdings (HKSE:01312) Headlines

No Headlines